• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Roflumilast for chronic plaque psoriasis associated with clearer skin

byConstance Wu
August 8, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. A significantly greater percentage of both roflumilast groups had clear or nearly clear skin compared to the control group after 6 weeks of treatment.

2. A numerically higher number of patients in the higher-dose group achieved the primary outcome, but no statistically significant difference was detected between the treatment groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Psoriasis is typically treated using topical glucocorticoids or vitamin D derivatives, but both options have significant downsides. For instance, glucocorticoids, while generally effective, are associated with slow-resolving adverse events such as cutaneous atrophy and striae distensae, and vitamin D derivatives sacrifice efficacy for safety yet still frequently cause local irritation. Phosphodiesterase type 4 (PDE-4) is involved in the regulation of numerous inflammatory mediators and has elevated activity in psoriatic skin. An oral PDE-4 inhibitor has been FDA-approved for the treatment of plaque psoriasis, but it is unclear whether topical inhibitors such as roflumilast also demonstrate substantial efficacy and safety. This double-blind phase 2b trial involving patients with psoriasis of at least mild severity was designed to evaluate the clinical profile of roflumilast at two dose levels. After 6 weeks of daily application of the topical cream, roughly three times as many patients in the roflumilast groups had clear or almost clear skin compared to the placebo group. Application-site reactions were equally common in both the active-treatment groups and the placebo group, but upper respiratory tract infection, the most common adverse event overall, occurred exclusively in the roflumilast groups. This study was limited by both a small sample size of patients with intertriginous psoriasis and a small sample size overall which precluded analysis of several secondary outcomes.

Click here to read the study, published today in NEJM

In-Depth [randomized controlled trial]: This study was conducted from September 2018 to May 2019 at 30 sites in the United States and Canada. 331 adult participants with scores of 2 or greater on the 5-point investigator’s global assessment (IGA) were randomly assigned in a 1:1:1 ratio to receive roflumilast 0.3% cream, roflumilast 0.15% cream, or vehicle (placebo) cream. Patients were excluded if they had above-normal exposure to UV radiation, were diagnosed with guttate or pustular psoriasis, or had received PDE-4 inhibitors within the previous month, among other criteria. At week 6, 28% of the patients in the roflumilast 0.3% group and 23% of those in the roflumilast 0.15% group had an IGA score of 0 or 1 (corresponding to clear and almost clear skin, respectively), compared to only 8% of those in the vehicle group (P<0.001 and P=0.004 vs. vehicle for roflumilast 0.3% and 0.15%, respectively). At week 12, this outcome was observed in 38% of the roflumilast 0.3% group, 32% of the roflumilast 0.15% group, and 16% of the vehicle group. Further, scores on the modified Psoriasis Area and Severity Index (PASI) decreased by 50% in the roflumilast 0.3% group, 49% in the roflumilast 0.15% group, and 17.8% in the vehicle group. Adjusted confidence intervals were not able to be calculated for either of these two secondary outcomes. Application-site reactions, gastrointestinal adverse events, rand psychiatric adverse events occurred at similar rates in all groups, and no meaningful between-group differences were observed in laboratory variables, electrocardiographs, or vital signs.

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention

#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease

Tags: chronic plaque psoriasispsoriasisroflumilast
Previous Post

Characteristics and strength of evidence of covid-19 studies registered on clinicaltrials.gov

Next Post

Further evidence that Zika virus disease associated with brain and eye birth defects

RelatedReports

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis
StudyGraphics

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

April 7, 2022
#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention
StudyGraphics

#VisualAbstract: Both dermatologists and patients with psoriatic disease expressed positive perspectives on strategies to improve cardiovascular disease prevention

January 28, 2022
#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease
StudyGraphics

#VisualAbstract Psoriasis is associated with an increase in incident venous thromboembolism and peripheral vascular disease

December 16, 2021
#VisualAbstract Risk of serious infection in patients with moderate to severe psoriasis is associated with the type of biologic treatment
StudyGraphics

#VisualAbstract Risk of serious infection in patients with moderate to severe psoriasis is associated with the type of biologic treatment

August 13, 2021
Next Post
Nanoparticle delivery of aurora kinase inhibitor may improve tumor treatment [PreClinical]

Further evidence that Zika virus disease associated with brain and eye birth defects

Initial data on the viability of SARS-CoV-2 in aerosol and on surfaces

Postexposure prophylactic use of hydroxychloroquine not effective for Covid-19 prevention

#VisualAbstract: Roflumilast for chronic plaque psoriasis associated with clearer skin

#VisualAbstract: Clinical validity of SARS-CoV-2 antibodies

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia
  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.